Introgen Therapeutics RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifFinanzen.nethttp://www.finanzen.netIntrogen Common Stock to be Delisted from the Nasdaq Stock Markethttp://www.finanzen.net/nachricht/aktien/Introgen-Common-Stock-to-be-Delisted-from-the-Nasdaq-Stock-Market-418141 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, ...http://www.finanzen.net/nachricht/aktien/Introgen-Common-Stock-to-be-Delisted-from-the-Nasdaq-Stock-Market-418141Introgen Files Voluntary Chapter 11 Petition to Facilitate Restructuringhttp://www.finanzen.net/nachricht/aktien/Introgen-Files-Voluntary-Chapter-11-Petition-to-Facilitate-Restructuring-417094 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> As part of its ongoing restructuring, Introgen Therapeutics, Inc. (NASDAQ:INGN), today announced that ...http://www.finanzen.net/nachricht/aktien/Introgen-Files-Voluntary-Chapter-11-Petition-to-Facilitate-Restructuring-417094Introgen Files Voluntary Chapter 11 Petition to Facilitate Restructuringhttp://www.finanzen.net/nachricht/aktien/Introgen-Files-Voluntary-Chapter-11-Petition-to-Facilitate-Restructuring-417099 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> As part of its ongoing restructuring, Introgen Therapeutics, Inc. (NASDAQ:INGN), today announced that ...http://www.finanzen.net/nachricht/aktien/Introgen-Files-Voluntary-Chapter-11-Petition-to-Facilitate-Restructuring-417099Introgen Restructures Operations to Focus on Revenue-Generating Manufacturing Capabilitieshttp://www.finanzen.net/nachricht/aktien/Introgen-Restructures-Operations-to-Focus-on-Revenue-Generating-Manufacturing-Capabilities-414457 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> Introgen Therapeutics, Inc. (NASDAQ:INGN), today announced that it has strategically reorganized the ...http://www.finanzen.net/nachricht/aktien/Introgen-Restructures-Operations-to-Focus-on-Revenue-Generating-Manufacturing-Capabilities-414457Introgen Announces the Transfer of its Listing of Common Stock from the Nasdaq Global Market to the Nasdaq Capital Markethttp://www.finanzen.net/nachricht/aktien/Introgen-Announces-the-Transfer-of-its-Listing-of-Common-Stock-from-the-Nasdaq-Global-Market-to-the-Nasdaq-Capital-Market-411018 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> Introgen Therapeutics, Inc. (NASDAQ:INGN), today announced that it has received notice from the <a ...http://www.finanzen.net/nachricht/aktien/Introgen-Announces-the-Transfer-of-its-Listing-of-Common-Stock-from-the-Nasdaq-Global-Market-to-the-Nasdaq-Capital-Market-411018Introgen Therapeutics Reports Third Quarter 2008 Financial Resultshttp://www.finanzen.net/nachricht/aktien/Introgen-Therapeutics-Reports-Third-Quarter-2008-Financial-Results-407127 <style type="text/css"> <!-- .bwcellpaddingbottom1 {padding-bottom: 2.0px} .bwcellpaddingbottom3 {padding-bottom: 4.0px} .bwcellpaddingleft0 {padding-left: 0.0px} .bwcellpaddingleft10 {padding-left: 50.0px} .bwcellpaddingleft2 {padding-left: 10.0px} .bwcellpaddingleft4 ...http://www.finanzen.net/nachricht/aktien/Introgen-Therapeutics-Reports-Third-Quarter-2008-Financial-Results-407127Introgen Receives Notification from Nasdaqhttp://www.finanzen.net/nachricht/aktien/Introgen-Receives-Notification-from-Nasdaq-388052 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, ...http://www.finanzen.net/nachricht/aktien/Introgen-Receives-Notification-from-Nasdaq-388052Introgen Receives Staff Determination Letter from Nasdaq Global Markethttp://www.finanzen.net/nachricht/aktien/Introgen-Receives-Staff-Determination-Letter-from-Nasdaq-Global-Market-376075 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, ...http://www.finanzen.net/nachricht/aktien/Introgen-Receives-Staff-Determination-Letter-from-Nasdaq-Global-Market-376075Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to Filehttp://www.finanzen.net/nachricht/aktien/Introgen-Receives-Notice-ADVEXIN-R-U-S-BLA-Not-Sufficiently-Complete-to-File-375244 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced that the United States ...http://www.finanzen.net/nachricht/aktien/Introgen-Receives-Notice-ADVEXIN-R-U-S-BLA-Not-Sufficiently-Complete-to-File-375244Introgen Therapeutics Reports Second Quarter 2008 Financial Results and Recent Corporate Highlightshttp://www.finanzen.net/nachricht/aktien/Introgen-Therapeutics-Reports-Second-Quarter-2008-Financial-Results-and-Recent-Corporate-Highlights-365328Introgen Therapeutics, Inc. (NASDAQ: INGN), a developer of targeted molecular therapies for cancer, announced today its financial results for the quarter and six months ended June 30, 2008, and highlighted recent corporate and product ...http://www.finanzen.net/nachricht/aktien/Introgen-Therapeutics-Reports-Second-Quarter-2008-Financial-Results-and-Recent-Corporate-Highlights-365328